# | Title | Journal | Year | Citations |
---|
1 | PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy | Molecular Cancer Therapeutics | 2015 | 1,787 |
2 | Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers | Molecular Cancer Therapeutics | 2017 | 1,779 |
3 | Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling | Molecular Cancer Therapeutics | 2008 | 1,237 |
4 | Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity | Molecular Cancer Therapeutics | 2008 | 1,095 |
5 | Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth | Molecular Cancer Therapeutics | 2011 | 1,062 |
6 | Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts | Molecular Cancer Therapeutics | 2004 | 1,040 |
7 | The Role of Autophagy in Cancer: Therapeutic Implications | Molecular Cancer Therapeutics | 2011 | 1,018 |
8 | MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted DrugsIn vitroandIn vivo | Molecular Cancer Therapeutics | 2010 | 821 |
9 | Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts | Molecular Cancer Therapeutics | 2004 | 812 |
10 | Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer | Molecular Cancer Therapeutics | 2014 | 774 |
11 | Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery | Molecular Cancer Therapeutics | 2006 | 701 |
12 | The role of the cyclin-dependent kinase inhibitor p21 in apoptosis | Molecular Cancer Therapeutics | 2002 | 676 |
13 | Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib | Molecular Cancer Therapeutics | 2014 | 627 |
14 | Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma | Molecular Cancer Therapeutics | 2007 | 612 |
15 | Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells | Molecular Cancer Therapeutics | 2006 | 607 |
16 | Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin | Molecular Cancer Therapeutics | 2008 | 580 |
17 | The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo | Molecular Cancer Therapeutics | 2001 | 552 |
18 | Tumor-stroma interactions in pancreatic ductal adenocarcinoma | Molecular Cancer Therapeutics | 2007 | 539 |
19 | DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation | Molecular Cancer Therapeutics | 2009 | 518 |
20 | Platinum neurotoxicity pharmacogenetics | Molecular Cancer Therapeutics | 2009 | 500 |
21 | A modeling analysis of the effects of molecular size and binding affinity on tumor targeting | Molecular Cancer Therapeutics | 2009 | 497 |
22 | Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity | Molecular Cancer Therapeutics | 2007 | 480 |
23 | Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor | Molecular Cancer Therapeutics | 2012 | 480 |
24 | Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells | Molecular Cancer Therapeutics | 2002 | 472 |
25 | Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells | Molecular Cancer Therapeutics | 2005 | 461 |
26 | Marine natural products as anticancer drugs | Molecular Cancer Therapeutics | 2005 | 459 |
27 | Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma | Molecular Cancer Therapeutics | 2014 | 457 |
28 | Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor | Molecular Cancer Therapeutics | 2010 | 456 |
29 | Discovery and development of anticancer aptamers | Molecular Cancer Therapeutics | 2006 | 449 |
30 | Metformin in Cancer Therapy: A New Perspective for an Old Antidiabetic Drug? | Molecular Cancer Therapeutics | 2010 | 444 |
31 | Matrix Metalloproteinase Inhibitors in Cancer Therapy: Turning Past Failures Into Future Successes | Molecular Cancer Therapeutics | 2018 | 444 |
32 | Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents | Molecular Cancer Therapeutics | 2009 | 443 |
33 | Antisense oligonucleotides: basic concepts and mechanisms | Molecular Cancer Therapeutics | 2002 | 441 |
34 | A Small-Molecule Inhibitor of Glucose Transporter 1 Downregulates Glycolysis, Induces Cell-Cycle Arrest, and Inhibits Cancer Cell Growth In Vitro and In Vivo | Molecular Cancer Therapeutics | 2012 | 439 |
35 | SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer | Molecular Cancer Therapeutics | 2003 | 438 |
36 | The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth | Molecular Cancer Therapeutics | 2005 | 435 |
37 | Epigenetics in cancer: Targeting chromatin modifications | Molecular Cancer Therapeutics | 2009 | 435 |
38 | Targeting Microtubules by Natural Agents for Cancer Therapy | Molecular Cancer Therapeutics | 2014 | 433 |
39 | Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance | Molecular Cancer Therapeutics | 2009 | 428 |
40 | Survivin, a cancer target with an emerging role in normal adult tissues | Molecular Cancer Therapeutics | 2006 | 420 |
41 | Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases | Molecular Cancer Therapeutics | 2006 | 410 |
42 | Molecular Biology of Bone Metastasis | Molecular Cancer Therapeutics | 2007 | 405 |
43 | In vitro and in vivo targeting of hollow gold nanoshells directed at epidermal growth factor receptor for photothermal ablation therapy | Molecular Cancer Therapeutics | 2008 | 392 |
44 | Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials | Molecular Cancer Therapeutics | 2014 | 385 |
45 | Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines | Molecular Cancer Therapeutics | 2003 | 381 |
46 | AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models | Molecular Cancer Therapeutics | 2007 | 377 |
47 | Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells | Molecular Cancer Therapeutics | 2008 | 377 |
48 | Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors | Molecular Cancer Therapeutics | 2014 | 375 |
49 | Mutation analysis of 24 known cancer genes in the NCI-60 cell line set | Molecular Cancer Therapeutics | 2006 | 374 |
50 | BRAFV600E: Implications for Carcinogenesis and Molecular Therapy | Molecular Cancer Therapeutics | 2011 | 373 |